esaxerenone

01/01/2023 - "Esaxerenone was effective in lowering nighttime home BP as well as morning and bedtime home BP and office BP, safe, and showed organ-protective effects in patients with uncontrolled nocturnal hypertension. "
01/01/2021 - "Thus, esaxerenone is a promising treatment option for patients with hypertension. "
12/01/2019 - "In conclusion, esaxerenone may be a promising treatment option for patients with hypertension."
01/01/2023 - "Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study."
04/01/2023 - "Esaxerenone is a nonsteroidal MRA with proven blood pressure-lowering efficacy that is currently licensed in Japan for treating hypertension. "

10/01/2023 - "A total of 8263 plasma esaxerenone concentrations from 166 healthy volunteers, 1097 hypertensive patients and 360 patients with diabetic nephropathy were pooled. "
01/01/2023 - "Thus, esaxerenone could be a UACR-reducing treatment option for patients with diabetic nephropathy."
11/01/2022 - "Clinical data of esaxerenone in hypertensive patients with diabetic kidney disease (DKD) are lacking. "
11/01/2022 - "Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetic Kidney Disease: A Multicenter, Open-Label, Prospective Study."
01/01/2022 - "In Japan, esaxerenone is approved for essential hypertension and has been studied in diabetic nephropathy. "

11/01/2022 - "Esaxerenone demonstrated a BP-lowering effect and improved albuminuria. "
01/01/2023 - "Esaxerenone can effectively reduce blood pressure in hypertensive patients and albuminuria in diabetic patients with CKD. "
10/01/2019 - "Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study."
10/27/2023 - "Esaxerenone or apararenone have both shown significant improvements in albuminuria versus placebo. "
01/01/2020 - "Thus, with careful monitoring of serum potassium, esaxerenone can be administered to patients with moderate renal impairment or both diabetes and albuminuria."

01/01/2023 - "The multicenter, randomized, open-label, parallel-group EXCITE-HT study will evaluate the efficacy and safety of esaxerenone as a second-line agent in the treatment of Japanese patients with uncontrolled essential hypertension. "
01/01/2019 - "In conclusion, esaxerenone is an effective and tolerable treatment option for patients with essential hypertension."
01/01/2019 - "Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study."
03/01/2019 - "In January 2019, based on positive results from a phase III trial conducted in Japan in patients with essential hypertension, esaxerenone received marketing approval in Japan for the treatment of hypertension. "
01/01/2022 - "In Japan, esaxerenone is approved for essential hypertension and has been studied in diabetic nephropathy. "

01/01/2021 - "Recently, a phase III clinical trial (ESAX-DN study) has also demonstrated the safety and efficacy of esaxerenone in patients with type 2 diabetes and microalbuminuria. "
10/01/2021 - "Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study."
01/01/2019 - "This phase 2 study evaluated the efficacy and safety of esaxerenone in Japanese patients with type 2 diabetes mellitus and microalbuminuria. "
01/01/2019 - "Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial."
12/07/2020 - "Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial."